Drugs / BRL-103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05442346 | Dec 2023 → Sep 2024 | beta-thalassemia major | Bioray Laboratories | Suspended | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRL-103 | “gene edited autologous hematopoietic stem cells with γ-globin expression; BRL-103” NCT05442346 ↗ |
| Modality | Cell therapy | “autologous hematopoietic stem cells” NCT05442346 ↗ |